CN108700589A - 用于检测和治疗食管癌的组合物和方法 - Google Patents
用于检测和治疗食管癌的组合物和方法 Download PDFInfo
- Publication number
- CN108700589A CN108700589A CN201780013902.0A CN201780013902A CN108700589A CN 108700589 A CN108700589 A CN 108700589A CN 201780013902 A CN201780013902 A CN 201780013902A CN 108700589 A CN108700589 A CN 108700589A
- Authority
- CN
- China
- Prior art keywords
- cdr
- sequences
- progastrin
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307189 | 2015-12-31 | ||
| EP15307189.9 | 2015-12-31 | ||
| EP16305139 | 2016-02-05 | ||
| EP16305139.4 | 2016-02-05 | ||
| PCT/EP2017/050037 WO2017114976A1 (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating esophageal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108700589A true CN108700589A (zh) | 2018-10-23 |
Family
ID=57821946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780013902.0A Pending CN108700589A (zh) | 2015-12-31 | 2017-01-02 | 用于检测和治疗食管癌的组合物和方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11789021B2 (https=) |
| EP (2) | EP3397967B1 (https=) |
| JP (2) | JP7018885B2 (https=) |
| KR (2) | KR102197478B1 (https=) |
| CN (1) | CN108700589A (https=) |
| AU (2) | AU2017204686B2 (https=) |
| BR (1) | BR112018013272A2 (https=) |
| CA (2) | CA3193481A1 (https=) |
| EA (1) | EA037032B1 (https=) |
| ES (2) | ES3003287T3 (https=) |
| PL (1) | PL3397967T3 (https=) |
| SG (1) | SG11201805263TA (https=) |
| WO (1) | WO2017114976A1 (https=) |
| ZA (1) | ZA201804142B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240018264A1 (en) * | 2015-12-31 | 2024-01-18 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating ovarian cancer |
| WO2019110662A1 (en) * | 2017-12-05 | 2019-06-13 | Progastrine Et Cancers S.À R.L. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
| JP7338128B2 (ja) | 2017-12-08 | 2023-09-05 | イー、シー、エス、ビオトラッカー、エス、エー、アール、エル | 癌診断における放射性標識プロガストリン |
| TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ｅｃｓ前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
| EP3759492A1 (en) | 2018-02-27 | 2021-01-06 | ECS-Progastrin SA | Progastrin as a biomarker for immunotherapy |
| JP7449640B2 (ja) * | 2018-03-13 | 2024-03-14 | クレアティブ マイクロテック インコーポレイテッド | 循環細胞を用いて被検者における治療反応及び疾患の進行をモニターする方法 |
| KR102167078B1 (ko) * | 2019-07-19 | 2020-10-16 | (주)파즈코리아 | 혈액 샘플 이송 장치 |
| WO2021081498A1 (en) * | 2019-10-24 | 2021-04-29 | The Johns Hopkins University | Compositions and methods for detecting and treating esophageal cancer |
| JP7287532B2 (ja) * | 2020-08-04 | 2023-06-06 | 王子ホールディングス株式会社 | トイレットロール |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102947337A (zh) * | 2010-01-08 | 2013-02-27 | 拜若提 | 用于治疗结肠直肠癌的方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20030021786A1 (en) * | 2001-07-09 | 2003-01-30 | Gevas Philip C. | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| DK1794586T3 (da) * | 2004-09-22 | 2013-05-13 | Cancer Advances Inc | Monoklonale antistoffer til progastrin |
| JP2009529915A (ja) * | 2006-03-20 | 2009-08-27 | ゾーマ テクノロジー リミテッド | ガストリン物質に対して特異的なヒト抗体および方法 |
| US7854932B2 (en) * | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| US20110085986A1 (en) | 2009-10-13 | 2011-04-14 | Pomila Singh | Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides |
| US9487582B2 (en) | 2010-01-08 | 2016-11-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for treating pancreatic cancer |
| US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
| JP5829672B2 (ja) | 2010-03-24 | 2015-12-09 | レ ラボラトワール セルヴィエ | 結腸直腸及び胃腸癌の予防 |
| US10533050B2 (en) | 2010-07-26 | 2020-01-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and compositions for liver cancer therapy |
| FI20145550A7 (fi) * | 2014-06-13 | 2015-12-14 | Biohit Oyj | Gastriini-17 käyttö biomarkkerina atrofiselle gastriitille ja usealle sen seurauksena kohonneelle riskille |
| WO2016066671A1 (en) * | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant cancers using progastrin inhibitors |
-
2017
- 2017-01-02 KR KR1020187020013A patent/KR102197478B1/ko active Active
- 2017-01-02 EA EA201891527A patent/EA037032B1/ru unknown
- 2017-01-02 US US16/067,208 patent/US11789021B2/en active Active
- 2017-01-02 SG SG11201805263TA patent/SG11201805263TA/en unknown
- 2017-01-02 ES ES20217589T patent/ES3003287T3/es active Active
- 2017-01-02 AU AU2017204686A patent/AU2017204686B2/en active Active
- 2017-01-02 CA CA3193481A patent/CA3193481A1/en active Pending
- 2017-01-02 CA CA3009785A patent/CA3009785A1/en active Pending
- 2017-01-02 EP EP17700483.5A patent/EP3397967B1/en active Active
- 2017-01-02 PL PL17700483T patent/PL3397967T3/pl unknown
- 2017-01-02 EP EP20217589.9A patent/EP3848709B1/en active Active
- 2017-01-02 KR KR1020207037405A patent/KR102430893B1/ko active Active
- 2017-01-02 ES ES17700483T patent/ES2861587T3/es active Active
- 2017-01-02 WO PCT/EP2017/050037 patent/WO2017114976A1/en not_active Ceased
- 2017-01-02 BR BR112018013272-1A patent/BR112018013272A2/en not_active IP Right Cessation
- 2017-01-02 JP JP2018534930A patent/JP7018885B2/ja active Active
- 2017-01-02 CN CN201780013902.0A patent/CN108700589A/zh active Pending
-
2018
- 2018-06-20 ZA ZA201804142A patent/ZA201804142B/en unknown
-
2020
- 2020-03-31 AU AU2020202296A patent/AU2020202296B2/en active Active
-
2022
- 2022-01-31 JP JP2022013712A patent/JP7363007B2/ja active Active
-
2023
- 2023-09-15 US US18/468,096 patent/US20240085423A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102947337A (zh) * | 2010-01-08 | 2013-02-27 | 拜若提 | 用于治疗结肠直肠癌的方法 |
Non-Patent Citations (1)
| Title |
|---|
| APING YUAN ET AL.: "Immunohistochemical Examination of Gastrin，Gastrin Precursors, and Gastrin/CCK-2 Receptor in Human Esophageal Squamous Cell Carcinomas", 《PATHOL. ONCOL. RES.》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017204686A1 (en) | 2018-07-05 |
| AU2017204686B2 (en) | 2020-04-30 |
| JP2019505785A (ja) | 2019-02-28 |
| JP7363007B2 (ja) | 2023-10-18 |
| US11789021B2 (en) | 2023-10-17 |
| BR112018013272A2 (en) | 2018-12-11 |
| KR102430893B1 (ko) | 2022-08-09 |
| CA3009785A1 (en) | 2017-07-06 |
| PL3397967T3 (pl) | 2021-06-28 |
| KR20210002363A (ko) | 2021-01-07 |
| EA037032B1 (ru) | 2021-01-28 |
| WO2017114976A1 (en) | 2017-07-06 |
| US20240085423A1 (en) | 2024-03-14 |
| CA3193481A1 (en) | 2017-07-06 |
| KR20180108586A (ko) | 2018-10-04 |
| ZA201804142B (en) | 2019-11-27 |
| AU2020202296A1 (en) | 2020-04-23 |
| EP3397967A1 (en) | 2018-11-07 |
| AU2020202296B2 (en) | 2022-06-02 |
| JP7018885B2 (ja) | 2022-02-14 |
| KR102197478B1 (ko) | 2021-01-04 |
| EP3848709A1 (en) | 2021-07-14 |
| US20190011447A1 (en) | 2019-01-10 |
| EP3397967B1 (en) | 2020-12-30 |
| EP3848709B1 (en) | 2024-12-04 |
| EP3848709C0 (en) | 2024-12-04 |
| ES3003287T3 (en) | 2025-03-10 |
| ES2861587T3 (es) | 2021-10-06 |
| EA201891527A1 (ru) | 2019-01-31 |
| SG11201805263TA (en) | 2018-07-30 |
| JP2022064969A (ja) | 2022-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240085423A1 (en) | Compositions and methods for detecting and treating esophageal cancer | |
| AU2021250840B2 (en) | Compositions and methods for detecting and treating ovarian cancer | |
| JP7478708B2 (ja) | 胃癌の検出および治療のための組成物および方法 | |
| US20240018264A1 (en) | Compositions and methods for detecting and treating ovarian cancer | |
| EA050261B1 (ru) | Способ in vitro диагностики рака яичников и способ мониторинга эффективности его лечения | |
| HK1262046A1 (en) | Compositions and methods for detecting and treating esophageal cancer | |
| HK1262046B (en) | Compositions and methods for detecting and treating esophageal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |